Principles of justice as the basis for public policy on psychopharmacological cognitive enhancement

Law, Innovation and Technology

Volumn 4, Issue 1, 2012, Pages 67-83

  Dubljevic, Veljko ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873935087     PISSN: 17579961     EISSN: 1757997X     Source Type: Journal    
DOI: 10.5235/175799612800650617     Document Type: Article

References (41)

1. Modafinil, under the brand name Provigil®, is the medical treatment for narcolepsy. However, it is increasingly used off-label for jet-lag and general effects of fatigue and sleep deprivation.
2. RE Ashcroft, ‘American Biofutures: Ideology and Utopia in the Fukuyama/Stock Debate’ (2003) 29 Journal of Medical Ethics 59;
3. E Parens, ‘Authenticity and Ambivalence: Toward Understanding the Enhancement Debate’ (2005) 35(3) Hastings Center Report 34.
4. M Selgelid, ‘An Argument against Arguments for Enhancement’ (2007) 1(1) Studies in Ethics, Law, and Technology Art 12.
5. G Khushf, ‘The Use of Emergent Technologies for Enhancing Human Performance: Are We Prepared to Address the Ethical and Political Issues?' (2005) 4(2) Public Policy and Practice, www.ipspr.sc.edu/ejournal/Archives0805.asp (accessed 10 July 2011).
6. R Campa, ‘Pure Science and the Posthuman Future’ (2008) 19(1) Journal of Evolution and Technology 28.
7. N Bostrom, ‘Smart Policy: Cognitive Enhancement in the Public Interest’ in L Zonneveld, H Dijstelbloem and D Ringoir (eds), Reshaping the Human Condition: Exploring Human Enhancement (The Hague:Rathenau Institute, in collaboration with the British Embassy, Science and Innovation Network and the Parliamentary Office of Science & Technology, 2008) 29.
8. N Agar, Liberal Eugenics: In Defense of Human Enhancement (Malden, 2005).
9. F Fukuyama, Our Posthuman Future (Picador, 2002).
10. US President’s Council on Bioethics, Beyond Therapy: Biotechnology and the Pursuit of Happiness (Washington, DC, 2003).
11. A Clark, Natural-Born Cyborgs: Minds, Technologies, and the Future of Human Intelligence (Oxford University Press, 2003).
12. J Habermas, Die Zukunft der menschlichen Natur (Suhrkamp, 2001);
13. A Buchanan, D Brock, N Daniels and D Wikler, From Chance to Choice: Genetics and Justice (Cambridge University Press, 2000).
14. B Maher, ‘Poll Results: Look Who’s Doping’ (2008) 452 Nature 674.
15. W Glannon, ‘Psychopharmacological Enhancement’ (2008) 1(1) Neuroethics 45;
16. W Sententia, ‘Cognitive Enhancement and the Neuroethics of Memory Drugs’ in W Bainbridge and M Roco (eds), Managing Nano-Bio-Info-Cogno Innovations: Converging Technologies in Society (Springer, 2006) 153;
17. W Riedel, ‘Psychopharmaceutical Cognition Enhancement’ in Zonneveld et al (n 6).
18. K Lieb, Hirndoping: Warum wir nicht alles schlucken sollten (Artemis & Winkler, 2010).
19. Maher (n 12).
20. H Greely, B Sahakian, J Harris, RC Kessler, M Gazzaniga, P Campbell and MJ Farah, ‘Toward Responsible Use of Cognitive-Enhancing Drugs by the Healthy: Policy Suggestions’ in MJ Farah (ed), Neuroethics-An Introduction with Readings (MIT Press, 2010) 73-78.
21. J Rawls, Political Liberalism (expanded edition) (Columbia University Press, 2005);
22. J Habermas, Between Facts and Norms (Polity, 2004).
23. TL Beauchamp and JF Childress, Principles of Biomedical Ethics (Oxford University Press, 6th edn 2008).
24. N Levy, Neuroethics (Cambridge University Press, 2007);
25. M Gazzaniga, The Ethical Brain (Dana Press, 2005);
26. E Racine, Pragmatic Neuroethics:Improving Treatment and Understanding of the Mind-Brain (MIT Press, 2010);
27. J Harris, ‘Chemical Cognitive Enhancement: Is it Unfair, Unjust, Discriminatory, or Cheating for Healthy Adults to use Smart Drugs?' in J Illes and B Sahakian (eds), The Oxford Handbook of Neuroethics (Oxford University Press, 2011) 265;
28. MJ Farah, ‘Neuroscience and Neuroethics in the 21st Century’ in Illes and Sahakian, The Oxford Handbook of Neuroethics 761.
29. Lieb (n 15) could be understood in this way, although it should be understood that he does not support enhancement.
30. J Savulescu, ‘Justice, Fairness, and Enhancement’ (2006) 1093 Annals of the New York Academy of Sciences 321.
31. J Rawls, Justice as Fairness: A Restatement (Harvard University Press, 2001) 42-43.
32. J Rawls, ‘The Idea of Public Reason Revisited’ (1997) 64 University of Chicago Law Review 765.
33. J Rawls, A Theory of Justice (Harvard University Press, rev edn 1999).
34. Rawls (n 19).
35. B Gert, CM Culver and KD Clouser, Bioethics-A Systematic Approach (Oxford University Press, 2006).
36. In what follows, I draw on Rawls (n 19), Lecture VI. It is important to note that Public reason should be understood in opposition to Nonpublic reason.
37. B Capps, ‘Libertarianism, Legitimation, and the Problems of Regulating Cognition-Enhancing Drugs’ (2011) 4(2) Neuroethics 119.
38. Buchanan et al (n 11) 270-272.
39. Buchanan et al (n 11).
40. Levy (n 22).
41. RH Blank, ‘Globalization: Pluralist Concerns and Contexts’ in J Giordano and B Gordijn (eds), Scientific and Philosophical Perspectives in Neuroethics (Cambridge University Press, 2010) 321-342.